Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Improving Margins ⢠Ongoing Losses GKOS has strong liquidity and improving cash generation, but persistent losses and a rich valuation mean the investment case still depends on turning near-term operating gains into durable profitability.
Price Behavior
Key Price Behavior Insights: ⢠Breakout support ⢠Higher lows ⢠Stretched range Support Level: $170-$171 Resistance Level: $189-$190 Over the last month, GKOS has stayed in a clear uptrend with a breakout above $170-$171 now acting as support, but after hitting a fresh short-term high near $189-$190 the stock looks stretched and could pause or pull back if it slips below $180.
Sentiment & News
Key News Insights: ⢠Record Sales ⢠Guidance Raise ⢠Trial Progress Glaukos reported record Q2 sales, narrower losses, and raised 2026 guidance as iDose TR/Epioxa momentum and PRESERFLO clinical progress reinforced a strong growth outlook.
AI Summary
GKOS is shifting from a long-duration R&D story to a scaled commercial platform with accelerating sales, expanding margins, and positive free cash flow, but the stock already prices in near-perfect execution so the key risk is whether management can sustain growth and de-risk clinical/regulatory drivers fast enough to justify the rich valuation.
Description
Glaukos Corporation develops ophthalmic medical devices and pharmaceutical therapies for glaucoma, corneal conditions, and retinal diseases. Its commercial portfolio centers on micro-bypass stents placed with cataract surgery to improve aqueous outflow in patients with mild-to-moderate open-angle glaucoma, while its pipeline includes a multi-stent system for refractory cases and a micro-scale injectable implant for sustained drug delivery. The company sells through a combination of direct sales and distributors in the U.S. and internationally and is headquartered in San Clemente, California, having been incorporated in 1998.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 20 | Aug 27 | GKOS | Glaukos Corporation | Q2 revenue increased 50% year over year to $185.6 million, the loss was narrower than expected, and 2026 sales guidance was raised; shares gained 23.8% and were testing $189.50 resistance on August 20. | Active | +0.0% |